Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tolerability and PK of Tolebrutinib (SAR442168) in Healthy Adults
NCT06106074Phase 1Completed
- Sponsor
- Sanofi
- Start
- Aug 2020
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of tolebrutinib in multiple sclerosis (MS) (5 arms), sponsored by Sanofi. Primary endpoints: Number of participants with Adverse Events (AEs) and treatment-emergent adverse events (TEAEs), Total (free and bound) SAR442168 concentrations in CSF and 3 more. Started Aug 2020; status: completed.
02
Drugs
tolebrutinib
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT06106074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06106074.